ArticleFrontiers in microbiology2025
Analysis of gut and circulating microbiota characteristics in patients with liver cirrhosis and portal vein thrombosis.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Machine learning-driven clinical decision support for liver cirrhosis: a gut microbiome-based web prediction model with explainable AI integration.BMC gastroenterology · 2026Article
- Gut microbiota involvement in the alteration of inflammatory cell infiltration and gut barrier integrity in liver cirrhosis.Biomedical reports · 2025Article
- Thrombotic Risk and Coagulation Imbalance in Cirrhosis and Hepatocellular Carcinoma: Clinical Implications and Management.Cancers · 2025Review
- Correlation between gut microbiota and their metabolites and the efficacy of chemotherapy combined with immunotherapy for extensive-stage small cell lung cancer.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Portal vein thrombosis (PVT) is a common and serious complication of liver cirrhosis, often associated with worsened prognosis and increased risk of hepatic decompensation. The role of gut and circulating microbiota in its pathogenesis remains unclear. Methods: We enrolled cirrhotic patients with PVT ( Results: (1) Gut microbiota showed no α-diversity difference between groups, but β-diversity differed significantly. PVT patients had increased Gram-negative bacteria (such as Conclusion: Intestinal dysbiosis and translocation in cirrhotic patients with PVT lead to differential changes in the portal and peripheral circulatory microbiomes. This may contribute to the formation of PVT by inducing endotoxemia and systemic inflammation, providing a new microbiological perspective on the pathogenesis of cirrhosis-related PVT through the gut-liver axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.